- The Washington Times - Monday, December 12, 2005

HOUSTON (AP) — The nation’s first federal Vioxx trial ended yesterday with a hung jury, but the case involving the 2001 death of a Florida man who took the once-popular painkiller for a month will be retried, a judge said.

The mistrial leaves Vioxx’s maker Merck & Co. with the prospect of facing a new jury that could hear accusations that the company withheld information from the New England Journal of Medicine about a 2000 Vioxx study, so the drug would appear safer.

Merck shares fell almost 3 percent as the trial’s outcome shook investors worried about the company’s liability in the thousands of pending Vioxx cases.

About 20 million people took Vioxx before Merck withdrew what had become a $2.5 billion seller from the market last year, after a separate, longer-term study showed the drug could double the risk of heart attack or stroke if taken for 18 months or longer.

“You can’t lie to people like the New England Journal of Medicine and get away with it,” said plaintiff’s lawyer Jere Beasley. “We look forward to the next trial.”



Merck lead attorney Phil Beck said that last week’s revelations from the medical journal would be a “nonissue” in a retrial and that Merck had supplied all the updated safety data to the Food and Drug Administration before the journal article was published.

The jury’s inability to reach a unanimous verdict apparently was unrelated to the journal revelations, which came late last week after deliberations began.

The journal reported Thursday that authors of a report about the Merck-funded study — including Merck’s head of clinical trials and a key witness for Merck, Dr. Alise Reicin — omitted three patients’ heart attacks in the data they submitted to the journal, making it appear that Vioxx caused four times, rather than five times, as many heart attacks as the painkiller naproxen.

The 2000 study has figured heavily in the first three Vioxx trials to reach juries — one in a Texas state court that Merck lost, another in its home state of New Jersey that the company won and in the federal case held in Houston.

Merck disclosed the full amount of heart attacks to the FDA in 2000.

The mistrial means Merck gained no momentum in its battle against about 7,000 pending state and federal Vioxx lawsuits and potentially billions of dollars in payouts.

The nine-member jury was about 20 minutes into its fourth day of deliberations when U.S. District Judge Eldon Fallon called the jurors in and reminded them they had agreed Saturday to reach a verdict in a “reasonable time.”

“It has now been a reasonable time. We cannot get a verdict,” Judge Fallon said, declaring a mistrial. Federal litigation requires a unanimous verdict.

Mr. Beck said Judge Fallon gave the jury enough time.

“At some point, if you are a judge you have to make a tough call and you say, ‘You know what? They have been at it long enough and if I make them stay any longer, then people are going to be questioning whether the verdict … really reflects the consent of nine people or not.’”

The jury couldn’t decide whether Merck was liable in Richard “Dicky” Irvin’s 2001 death and whether the company failed to issue safety warnings that the drug could have serious cardiovascular side effects.

Merck argued that Vioxx was not a factor in Mr. Irvin’s death because he took the drug for about a month, and the long-term study that led to the drug’s withdrawal last year showed dangers only after 18 months’ use. The company blamed his death on clogged arteries and a blood clot that led to the heart attack.

Mr. Irvin, a former college football player who managed a wholesale seafood company in St. Augustine, Fla., got a prescription for Vioxx from his son-in-law, an emergency-room physician, without a medical checkup.

His wife, Evelyn Irvin Plunkett, said Vioxx — which inhibits an enzyme that promotes inflammation and thins the blood — led to the clot formation.

The judge said he would confer with attorneys next week to set a retrial date.

Merck shares fell 72 cents, or 2.5 percent, to close at $28.41 yesterday on the New York Stock Exchange.

Sign up for Daily Newsletters

Manage Newsletters

Copyright © 2021 The Washington Times, LLC. Click here for reprint permission.

Please read our comment policy before commenting.

 

Click to Read More and View Comments

Click to Hide